Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ARCUS BIOSCIENCES, INC.

(RCUS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Wedbush Lifts Price Target on Arcus Biosciences to $67 From $52 After Gilead Opts In to 3 Programs; Outperform Rating Kept

11/19/2021 | 07:46am EST


ę MT Newswires 2021
All news about ARCUS BIOSCIENCES, INC.
01/25Arcus Biosciences Announces New Employment Inducement Grants
BU
01/14Goldman Sachs Adjusts Arcus Biosciences' Price Target to $43 From $45; Neutral Rating K..
MT
01/11Arcus Biosciences Announces New Employment Inducement Grants
BU
01/10Arcus Biosciences Provides Update on Clinical Programs, Including Key 2022 Milestones
BU
01/10Arcus Biosciences Provides Update on Clinical Programs, Including Key 2022 Milestones
CI
2021Arcus Biosciences Announces New Employment Inducement Grants
BU
2021INSIDER SELL : Arcus Biosciences
MT
2021ARCUS BIOSCIENCES, INC. : Other Events (form 8-K)
AQ
2021Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-sta..
BU
2021INSIDER SELL : Arcus Biosciences
MT
More news
Analyst Recommendations on ARCUS BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 169 M - -
Net income 2021 -248 M - -
Net cash 2021 987 M - -
P/E ratio 2021 -8,10x
Yield 2021 -
Capitalization 2 057 M 2 057 M -
EV / Sales 2021 6,33x
EV / Sales 2022 5,74x
Nbr of Employees 236
Free-Float 62,7%
Chart ARCUS BIOSCIENCES, INC.
Duration : Period :
Arcus Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARCUS BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 29,28 $
Average target price 64,40 $
Spread / Average Target 120%
EPS Revisions
Managers and Directors
Terry J. Rosen Chairman & Chief Executive Officer
Juan Carlos Jaen President & Director
Robert C. Goeltz Chief Financial & Accounting Officer
Steve Young Senior VP-Technology & Quantitative Biology
Kartik Krishnan Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
ARCUS BIOSCIENCES, INC.-27.65%2 057
MODERNA, INC.-38.99%62 828
LONZA GROUP AG-20.54%48 784
IQVIA HOLDINGS INC.-17.54%44 443
SEAGEN INC.-20.08%22 592
ICON PUBLIC LIMITED COMPANY-18.28%20 601